Predictive marker

Miyata, Y, H Sakai, T Hayashi, and H Kanetake. 2003. Serum insulin-like growth factor binding protein-3/ prostate-specific antigen ratio is a useful predictive marker in patients with advanced prostate cancer. Prostate 54 125-132. 

It is important to recognize that establishing a model reference material, such as the protein-embedding model described above, while essential, is just the first step for standardization of IHC. Further studies will be required to develop mathematically conversion factors, and to explore the potential utility and limitations of this approach for different proteins that are of clinical interest, as diagnostic, prognostic, or predictive markers, as described above.1012... 

Pegram MD, Pauletti G, Slamon DJ. HER-2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res Treat 1998 52 65-77. 

Molecular Biology of 5-FU Metabolism Current Standard of Care for Metastatic Colorectal Cancer Pharmacogenomics and Prognostic AND Predictive Markers Thymidylate Synthase Polymorphisms TS Polymorphisms as Prognostic AND Predictive Factors Other Polymorphisms of the 5-FU Metabolism Conclusion References... 

BRCAi A Potential Predictive Marker for CiSPLATIN AND DOCETAXEL BRCAi IN THE Transcriptional Regulation OF Spindle Checkpoint Genes Clinical Trials of Customized Chemotherapy References... 

The same premises of customization can be applied to early NSCLC. Various clini-eal observations indieate that when these defense NER genes are overexpressed in re-seeted NSCLCs, they reflect a lower risk of relapse and increased cisplatin resistance. Several layers of evidence show that BRCAl can be the most important predictive marker for eustomizing chemotherapy. In addition, the clinical value of several mitotic checkpoint genes that are dysfunctional in NSCLC and regulated by BRCAl should also be investigated. 

Fig. 2. BRCAl involved in regulation of mitotic checkpoint genes. (Reprinted with permission from Mullan et al. BRCAl A good predictive marker of drug sensitivity in breast cancer treatment Biochim Biophys Acta, in press,with kind permission from Elsevier).

Rosell R, Felip E, Taron M et al. Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery. Clin Cancer Res 2004 0 42 5s-42 9s. 

There are emerging genomic predictive markers for trastuzumab resistance (e.g., high IGF-IR and loss of PTEN (32,33), that do not appear to preclude clinical response to lapatinib (34). The ability to distinguish patients who benefit from one drug vs. another, based on PGX markers, is of obvious clinical interest. These examples illustrate that... 

Pusztai L, Hess KR. Clinical trial design for microarray predictive marker diseovery and assessment. Ann O co/2004 15 1731-1737. Review. 

Mania-Pramanik J, Potdar SS, Vadigoppula A, Sawant S. Elastase A predictive marker of inflammation and/or infection. J Clin Lab Anal 2004 18 153-158. 

Knoop AS, Knudsen H, Balslev E, Rasmussen BB, Overgaard J, Nielsen KV, et al. retrospective analysis of topoisomerase lla amplifications and deletions as predictive markers in primary breast cancer patients randomlyassignedtocyclophosphamide, methotrexate, andfluorouracilor cyclophosphamide, epirubicin, and fluorouracil Danish Breast Cancer Cooperative Group. J Clin Oncol 2005 23(30) 7483-90. 

---